Details of the Drug Combinations

General Information of This Drug (ID: DMHIDCJ)

• Drug Name: Octreotide (DMHIDCJ)
• Synonyms: Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

Indication

Acromegaly; ICD 11: 5A60.0; Status: Approved [1]; Carcinoid syndrome; ICD 11: 5B10; Status: Approved [2]; Diabetic retinopathy; ICD 11: 9B71.0; Status: Approved [2]; Neuroendocrine cancer; ICD 11: 2B72.1; Status: Investigative [2]

• Therapeutic Class: Anabolic Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ceftriaxone + Octreotide	DCDHZFS	Ceftriaxone	Variceal Hemorrhage	[3]
Octreotide + Motesanib	DCNB7G5	Motesanib	Gastrointestinal Carcinoid Tumor	[4]
Everolimus + Octreotide	DCNH19Z	Everolimus	Recurrent Meningiomas	[5]
Lapatinib + Octreotide	DC06496	Lapatinib	Cancer	[6]
Octreotide + Temozolomide	DC45YKA	Temozolomide	Midgut Neuroendocrine Tumours	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2055).
• [2] Octreotide FDA Label
• [3] ClinicalTrials.gov (NCT03061604) RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding
• [4] ClinicalTrials.gov (NCT00427349) AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
• [5] ClinicalTrials.gov (NCT02333565) Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
• [6] ClinicalTrials.gov (NCT02294786) Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
• [7] ClinicalTrials.gov (NCT02358356) Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study